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Abstract 
 
Medical Informatics (MI) and Bioinformatics (BI) are two interdisciplinary areas located at the 
intersection between computer science and medicine and biology, respectively. Historically, 
they have been separated and only occasionally have researchers of both disciplines 
collaborated. The completion of the Human Genome Project has brought about in this post 
genomic era the need for a synergy of these two disciplines to further advance in the study of 
diseases by correlating essential genotypic information with expressed phenotypic information. 
Biomedical Informatics (BMI) is the emerging technology that aims to put these two worlds 
together in the new rising genomic medicine. In this regard, institutions such as the European 
Commission have recently launched several initiatives to support a new combined research 
agenda, based on the potential for synergism of both disciplines. In this paper we review the 
results the BIOINFOMED study one of these projects funded by the EC.  
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Introduction 
 
The complete sequencing of the Human Genome has opened, in this post-genomic era, new 
perspectives for the study of monogenic and complex multigenic diseases, the later being more 
prevalent. As our knowledge about the human genome increases so does our belief that to fully 
grasp the mechanisms of disease we need to understand  the complex interplay among genes 
and environmental factors that initiate pathological processes. Therefore,  allowing scientists to 
obtain those data needed to close the classical equation (genotype + environment = phenotype).  
 
The new genetic and proteomic data has brought forth the possibility of developing new targets 
and therapies based on these findings, of implementing newly developed preventive measures 
and also of discovering new research approaches to old problems. To carry out the work it is 
important to be able to deal with the large amount of data generated in the laboratory by 
functional genomics and proteomics (Bioinformatics). Also, it is just as necessary to integrate 
the information derived from this data into the electronic health records together with the 
knowledge generated in the clinical setting (Medical Informatics). The coupling of BI with the 
tools and techniques that deal with clinical information (e.g. electronic health records, clinical 
decision systems, image- and signal-processing), will allow to correlate essentially genotypic 
information with expressed phenotypic information. Biomedical Informatics (BMI) is the 
emerging technology that aims to put these two worlds together in order to participate in the 
discovery and creation of novel diagnostic and therapeutic methods in the new rising genomic 
medicine.  
 
The need for an integrated approach to medicine was mentioned by the WHO “Some of the 
claims for the medical benefits of genomics have undoubtedly been exaggerated, particularly 
with respect to the time scales required for them to come to fruition. Because these 
uncertainties, it is vital that genomics research is not pursued to the detriment of well-
established methods of clinical practices, and clinical and epidemiological research. Indeed, 
for its full exploitation it will need to be integrated into clinical research involving patients and 
into epidemiological studies in the community. It is crucially important that a balance is 
maintained in medical practice and research between genomics and these more conventional 
and well tried approaches”. 
 
Background  
 
Medical informatics (MI) and bioinformatics (BI) are two interdisciplinary areas located at the 
intersection between informatics and medicine and biology (genomics), respectively. 
Historically, they have been separated and only occasionally have researchers of both 
disciplines collaborated in the past. Almost from its very beginning MI mainly focused on the 
development of practical computer applications for health purposes. Recently, a debate has 
opened up about its scientific content and future. Meanwhile, BI is a younger discipline, which 
has grown enormously thanks to its contribution to genomic research. 
 
BI and MI until recently had no reason for synergy. It is the elucidation of the human genome 
what has promoted the need for a synergy between the two. Classical epidemiology and 
clinical research on the one hand, and genomic research on the other, alone are no longer 
 
 
enough for advancing in genomic medicine, and a new integrative approach is required. The 
integration of all the data and information generated at all levels requires synergy of 
Bioinformatics and Medical Informatics.  
 
The history of the development of BI is different of that of MI. While the latter has been 
around since the introduction of computers in the hospitals and was developed mainly from an 
application-centred perspective, BI was developed to handle large amounts of data, mainly 
sequences, generated in the laboratories. Nowadays, there are a number of initiatives that 
combine elements of the two areas up to the point of an integrated approach on databases, 
standards, analysis, applications and education. This evolution towards joint actions is also 
observed in scientific meetings and publications.  
 
At present the interaction between the two communities, medical informatics and 
bioinformatics, is increasing as shown by the number of congresses and conferences that deal 
with this subject.  The need for this new interdisciplinary area has been realized by different 
institutions and entities. The American Medical Informatics Association, for example, has 
considered such interaction between MI and BI as the focus for its recent conferences. There 
are also cross programming of activities (panels, tutorials, sessions) in main congresses in both 
fields (MEDINFO, AMIA, MIE, ISMB, PSB, RECOMB),  conferences and special issues of 
journals dedicated to the intersection and mutual interests, the inclusion of bioinformatics in 
training programs of health centers and medical schools, and the collaboration with the 
pharmaceutical industry for physician training and technical support in genomics.  
 
The Conference “Synergy between Research in Medical Informatics, Bioinformatics and 
Neuroinformatics”, (Brussels, Dec. 14th, 2001, www.ramit.be), organised under the Belgian 
Presidency of the European Union, by the Belgian Federal Ministries of Social Affairs and 
Public Health and the European Commission - Directorate General Information Society and 
Directorate General Research also followed this line of work. More than 400 participants 
gathered in Brussels, to discuss the scientific and developmental issues involved in MI and BI 
related to future healthcare.  
 
This conference was the kick-off point for the activities related to the BIOINFOMED project 
(“Prospective Analysis of the Relationships and Synergy Between Medical Informatics and 
Bioinformatics”). The aim was to analyse the relationships and potential synergies between MI 
and BI. Several goals were set to be met during the duration of the project, among these there 
was the writing of a white paper were a research agenda was identified based on the potential 
for synergism of both disciplines. Several experts out of the almost 400 that attended the 
conference and that were particularly interested in the subject were invited to collaborate in the 
writing of a white paper with the group carrying out the project at the Institute of Health 
“Carlos III” (ISCIII), together with the Polytechnic University of Madrid and the University of 
Linköping. Two group work meetings were held, one in Crete (Greece) and another one in 
Valencia (Spain). 
 
The group in charge of the project at the Institute of Health “Carlos III” (ISCIII) designed a 
questionnaire to identify research questions, areas, research directions, and potentials of 
already existing tools and disciplines within MI that could be applied in BI and vice versa. 
Once the team at the ISCIII processed the answers, these were used as a starting point for the 
paper, which included a brief background and an overview of the expected impacts that the 
 
 
integration of clinical and genetic information facilitated by the synergy between BI and MI 
could have within the different sectors of society, as well as the proposed R&D agenda. 
 
There are, however, barriers in the application and development of new activities required for 
the integrated approach. These barriers can be overcome by collaborative efforts between the 
two disciplines thus bridging the existing gaps. 
 
Biomedical Informatics (BMI), rising from the synergy between BI and MI, provides the 
framework for developing and sharing new biomedical knowledge. New knowledge about the 
causes and treatments of disease will not be created as quickly without a dynamic, rational 
biomedical information environment. Since the creation of new knowledge is often 
accompanied by anxiety, BMI should provide clear ways of alleviating anxiety by properly 
informing all the stakeholders in the biomedical world of risks and realities. In order that the 
field develops at a proper pace, a dispassionate discussion of the impacts of the biomedical 
revolution is essential. In order that clinical care and basic biological investigations continue to 
address the health of the citizen, BMI must be effectively resourced.  
 
Expected Impacts 
 
In our view, the biomedical community seeks to remove the walls between biological 
information and medical information, to foster communication between clinician and scientist, 
and to enhance understanding between citizen and health care professionals. Our commitment 
to interoperability of biological and medical information for all appropriately authorised users 
creates imperatives, opportunities, and challenges. Equally significant demands are made by 
the evolution from patient-centred systems to citizen-centred systems that actively engage 
citizen participation.  
 
a. Scientists / Researchers 
 
They must become accustomed to exchanging and sharing medical and biological information 
and knowledge in global (often virtual) work settings. In addition, all workers will be 
challenged to more directly consider the ethical implications of research activities and to more 
deeply comprehend the repercussions of their work.  
 
Clinical Trials 
 
Biomedical databases are urgently needed to provide a sound scientific basis for what kind of 
genetic tests make sense and which tests just make healthy people anxious about their future. 
BMI bears a significant potential to clarify the sensitivity and sensibility of genetic testing.  
 
 
b. Health Care Professionals 
 
New knowledge and technology 
 
The very nature of BMI highlights the blurring of hitherto comfortable distinctions between 
clinical and molecular information. As we extend the concept of phenotype (“the visible 
 
 
                                                
properties of an organism that are produced by the interaction of the genotype and the 
environment”1) to encompass diseases as well as hair colour and body shape, we also expand 
the “properties” that are “visible” to include sub-cellular structures and physiological 
processes. One of the major impacts of BMI will be a broader understanding of how minute 
variations in DNA sequences, protein synthesis and subsequent protein function affect the 
evolution of diseases. Genomic and proteomic data analysis has already hastened both the 
elucidation of causes for disease and the development of drugs to combat disease. As our 
knowledge about molecular causes of disease increases, we can expect more elegant molecular 
interventions to diagnose, disrupt or ameliorate disease. BMI professionals may provide 
methods and tools for R&D in these issues. Greater magnification will be focused on how 
many different environmental changes affect phenotypic expression of genetic information. 
 
Professionals in supportive role 
 
Even as full-scale BMI exercises can create more knowledge, they can also create more 
anxiety. Genetic counselling will become an even more important part of clinical, hands-on 
care. We see a place for “culture brokers” – i.e. people who can translate between science and 
clinical care and between science and the “self caring” citizen.  
 
 
c. Individual Citizens 
 
The citizen “at risk” 
 
New BMI approaches can result in the creation of a new role –“citizen-at-risk.” As the 
knowledge base about genetic associations with illnesses becomes larger, it is likely that this 
identifiable “at risk” group will enlarge, encompassing many asyptomatic citizens and 
therefore placing new demands on health care systems. 
 
Informing citizens 
 
It will be very important for the European health delivery systems to establish and publish 
standards for rational genetic testing. The average citizen must be able to understand and gage 
the appropriate balance between the potential for improvement in health and the potential 
drawbacks that could arise from such testing. 
 
  
d. Health Care Providers and Systems 
 
Technology diffusion and scientific evidence 
 
European health care systems will face difficult challenges with the emergence of novel BMI 
applications: how and when to adopt them, particularly since new health technologies tend to 
be more expensive than old ones. In regard to several modern technologies, adoption has not 
followed a rational, evidence-based pattern. Biomedical informatics applications should not be 
 
1 Merriam Webster’s Collegiate Dictionary – Merriam-Webster, Incorporated, Springfield, MA, 1995 
 
 
brought into use as a result of market push. Rather, health care providers should be prepared to 
carefully select technologies that have been proven safe and effective. If required, providers 
should limit the adoption of new technologies to appropriate scientific research settings.    
 
Feasibility of current care practices 
 
Current treatment models may become obsolete as new biomedical knowledge is created. 
Health care providers should pay special attention to current developments in the field of BMI 
in order to be able to predict practical implications for everyday diagnostic/treatment routines. 
 
Public health and disease prevention 
 
Knowledge generated through very large biomedical databases will enable health care 
organisations to identify citizens who are not only at “genetic” risk for developing illnesses but 
whose risk of developing symptomatic illness could be reduced by one or more interventions. 
As we identify more and more genetically “at risk” citizens, more focused management 
programs must evolve. 
 
e. Policy - Decision makers 
 
Investment for the future 
 
Rational biomedical databases of the scope required for modern molecular research are 
expensive to establish and maintain. Spending adequate time on system design and architecture 
may pay off in the long run. Programmed cooperation between government, academia, and 
industry is absolutely essential.  
 
Prioritisation 
 
No health care system is able to provide the best possible care for each and every condition; 
some level of prioritisation is done -either consciously or unconsciously. Genetic testing and 
the associated concept of "citizen-at-risk" will constitute yet another aspect to the prioritisation 
palette.  
 
Legislative initiatives 
 
Biomedical informatics will bring about several ethical and societal issues that warrant careful 
societal discussion. Policy makers should see to it that they initiate and foster such discussion 
at an appropriate time, thereby providing citizens with adequate information to participate. The 
use of novel biomedical informatics applications will require clear and up-to-date legislation. 
Policy makers will have to foster a proactive and continuous legislative process that will keep 
up with the pace of current scientific developments and implementation plans.  
  
f. Industry 
 
In order for certain industrial efforts to succeed (such as pharmaceutical and bio technology), 
more attention will have to be paid to how both clinical trials and exploratory analyses evolve 
and become successful. Industries taking advantage of the development and maintenance of 
 
 
large data bases and knowledge bases by academic institutions should contribute to the 
financing of such public initiatives and collaborative efforts among different institutions. 
 
g. Society 
 
Consent to collect, view and use information 
 
Genomic and proteomic databases must be secure from unwanted intrusions. Correlation 
between clinical profiles and genomic/proteomic profiles should only take place when 
informed consent has been obtained. Public health reasons for violating these principles must 
be explicit and must result from public debate. Further, every citizens’ rights to not know about 
his/her genetic risk should be respected.  
 
Genetic discrimination 
 
 Any citizen would be uneasy about knowing that he/she was at risk for an illness that could 
lead to diminished job performance and very concerned about having such information 
available to third parties such as employers, insurers, financial institutions, etc. Scenarios of 
selection or exclusion on the basis of individuals' “genetic profiles” are not acceptable and this 
fundamental principle should be guaranteed through pertinent legislation. 
 
Racial profiling 
 
Today, a “racial profile” based on genetic information derived from blood analysis is 
commercially available to anyone, although the meaning of such information is not at all clear. 
Scientists are already engaged in debates about ethnicity vs. race, and one can see how “genetic 
assessments” of this sort are invitations for misusing large biomedical databases. Great care 
must be taken to see that biomedical databases are not subjected to unauthorized analyses of 
this sort. 
 
Fetal testing and pregnancy termination 
 
At the present time, pregnant women may elect to have pregnancies terminated as a result of 
genetic testing of the fetus. As more knowledge is created about genotypes at risk for disease, 
more couples will be faced with decisions about whether to have fetal testing performed and 
whether to act on the results of such testing. 
 
 
Gaps and bridging solutions 
 
a. Gaps 
 
Historically, MI and BI researchers have addressed different issues, used different 
methodologies, and got distinct sources of funding. MI matured in the broad and complex 
medical domain that is not only characterised by the delivery of patient care by many different 
specialists, but also involves, among others, research, administration, and management. 
Compared to MI, bioinformatics is more focussed, not only because of the human genome 
 
 
project, but also because the main purpose of BI is to enable and support research. While the 
tools and applications developed by MI reach a wide range of users including physicians, 
nurses, administrators, management, and researchers. BI applications are characterised by a 
much more homogeneous user group dominated by researchers. 
 
Although the application domains differ, both MI and BI will often use similar methodologies; 
both fields are active in machine learning, natural language processing, image analysis, or data 
mining in large databases. Working on similar problems with related methods, however, does 
not guarantee similar results because the application domains differ.  
 
Another striking difference between the MI community and the BI community involves the 
degree of interaction between the research groups. In MI, collaborative efforts and research 
between different groups has been relatively scarce. In BI, collaborative research has been a 
key issue for success. This difference in sharing and exchanging research results has led to a 
significant number of open-source programs and information resources in BI whereas efforts in 
MI have often been local and private. 
 
The different application domains are also reflected in education. The typical MI trainee gets 
his/her education in a medical setting (often the medical school) whereas the focus in BI is in 
biology. The cognitive reasoning, classical teaching and terminologies are different in 
medicine and biology, limiting an immediate transfer or unification of courses. 
 
b. Bridging solutions 
 
Although the roots of BI and MI are located in different application domains, these domains 
will increasingly overlap. Results of research in molecular medicine will have an impact on 
clinical medicine. The shared application domain will provide a natural place to collaborate. 
Medicine will benefit from the achievements of biological research, and biology will benefit 
from the use of clinical data for research. As the domains begin to overlap, both communities 
increasingly will share a common goal, a common context, for exploring collaboration. 
Examples include the development of ontologies and taxonomies, the use of natural language 
processing, or information retrieval.  
 
Two principal factors will drive the collaboration. First, the results of research in molecular 
biology will increasingly move toward clinical research and clinical practice providing a 
natural, shared issue: the application in daily practise. Second, the methodologies used by BI 
and MI will prove to have many similarities allowing exchange of experience between the 
fields. Finally, we should appreciate the changes biomedical science in general is going 
through. We are moving from a period of data starvation to a period of data overload – both in 
terms of research and patient data. We are standing on the threshold of a new era: we 
desperately need computers not only to store the data we collect, but also to store, verify and 
expand the partial interpretations we are constructing of those data. Therefore, we suggest that 
future initiatives should fall into three categories: Stimulating information exchange, initiating 
collaborations between the communities and fostering a new generation of scientists that speak 
both languages. 
 
 
 
Through our analysis we have seen the potential that both disciplines pose for an interaction. 
Not only do they share many interests, methods and tools but also each presents some 
complementary needs for the other.  
 
The research agenda shows the strategies and solutions that come from three different points of 
view or directions based on the flow of data and information attending to the disciplines in 
which they are generated, processed and maintained. These are: what can MI contribute to 
functional genomics, what can BI contribute to individualised healthcare, and the new area of 
BMI, combined approaches included, and its contribution to genomic medicine. All these 
based on the enabling technologies necessary for the development of the solutions proposed in 
each of the above mentioned areas. This is further described below and graphically shown in 
figures 1 through 4.  
  
 
• MI in support of Functional Genomics. Functional Genomics requires patient data coming 
from clinical information systems (laboratory tests, annotation of biological samples or 
familial history). MI can and should, therefore, play a role in facilitating this data for post-
genomic research.  
 
• BI in support of individualized Healthcare.  The practice of medicine moves into the post-
genomic era, there will be an increasing need for the practicing clinician, as well as for the 
medical informatician, to understand and use molecular level data. Knowledge of the 
concepts involved in acquiring, representing, analysing, and integrating such data falls in 
the scope of the bioinformatician. The collaboration between both disciplines will allow the 
real integration of genetic data of the patients in clinical information systems.  
 
• BMI in support of Genomic Medicine. Which represents the development of a new 
discipline, BMI that deals with integrated approaches oriented towards analysing the 
knowledge of diseases or the personalization of clinical solutions using information coming 
from the different levels (molecular, clinical or environmental) that take part in disease 
development. BMI has to do with new perspectives that require the knowledge and the 
abilities to deal with multi-level information.  
 
• Enabling Technologies. A sound and efficient computing, information and communication 
platform, a new generation of integrated analytical devices and virtual learning 
environments will play a key role in facilitating the implementation of all these scientific 
approaches upon which the research lines described in this work can be developed.  
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
This diagram reflects the interdisciplinarity of both MI and BI as well as of the new emerging 
disciplines of Genomic Medicine and BMI. The arrows show the different perspectives related 
to potential synergies among the above described areas.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
 
The diagram above shows the logical flow of data between MI and BI promoting synergy 
between the two disciplines. The top part of the diagram shows how data collected by medical 
informaticians during regular clinical practice and research, for example symptoms and signs 
or clinical laboratory data, can be made available in certain conditions (anonymized) to the 
bioinformaticians so they can utilize it in functional genomics. The incorporation of these data 
will allow to further advance in the research of the molecular bases of disease and to relate 
them to the genotypic characteristics of the patients. The bottom part of the diagram shows 
how data arising from research in functional and individual genomics processed and managed 
by bioinformaticians like, for instance, gene profiles, SNPs or haplotypes, can be incorporated 
in clinical information systems to complete patient records and to further care and personalized 
treatment of patients, as well as on the prevention of diseases and on clinical research. 
 
 
 
 
Figure 3 
 
The diagram depicts the actual and future development of technologies used in these fields. All 
these technologies are necessary for MI and BI. However some of these technologies like 
probabilistic expert reasoning, standards or vocabularies among others, are mainly developed 
in MI but they are of use in BI. In turn BI have developed further certain technologies, for 
instance database integration and automatic annotation that can also be used by medical 
informaticians. The middle part of the figure shows technologies that have received recently 
big attention because they are or will be needed in both disciplines and will of course be 
utilized by genomic medicine to improve and enhance healthcare, including here personalized 
healthcare, preventive medicine and molecular medicine. 
 
 
 
 
 
Figure 4 
 
The top part of this diagram reflects that the use of data handled by MI and the incorporation of 
the technologies shown in Figure 3 enable the development of applications that could be 
included within molecular medicine, for example disease reclassification. The bottom part of 
the figure shows that the utilization of the data coming from functional genomics research 
processed by the technologies mentioned in Figure 3 give rise to new applications included in 
what is called personalized medicine based on genomics such as telemedicine or clinical trials. 
Applications that have emerged or will emerge in which the synergy between both disciplines 
is obvious are shown in the middle part of the diagram. 
 
 
Collaborative agenda for BI and MI 
 
A total of 18 research lines have been identified.  
 
a. MI IN SUPPORT OF FUNCTIONAL GENOMICS 
 
Genomic researchers will need to draw inferences about the molecular mechanisms of diseases. 
Therefore access and integration of data coming from the clinical setting is essential for 
functional genomics research. The challenge for medical informaticians is to adapt existing 
systems or to develop new ones to allow this exchange of data.  
 
 
 
Phenotype databases for clinical annotation of biological samples and clinical validation of 
biological research results 
 
The application of new technologies derived from the discoveries in genomics and proteomics 
requires (1) accurate definition of the clinical characteristics of each patient (the “phenotype”) 
in a structured and computerized representation, (2) computational capabilities to interpret the 
large amounts of new, raw data and ability to store and retrieve the derived data in relational 
databases (the “genotype” and “proteotype”), and (3) processing tools and power to discover 
new relationships between the phenotype, genotype and proteotype, and create new 
knowledge.  
 
To obtain new knowledge from the genomic and proteomic data we need to combine the 
phenotype, genotype and proteotype of very large numbers of patients, ideally from different 
parts of the world. This will only be possible if the medical community adapts standardized 
annotation of biological samples (description of the phenotype), and develops laboratory 
procedures that will allow comparison of genomic and proteomic test results. Standardized 
description of the phenotype can be achieved by structured, physician data entry (a priori 
definition of structured data elements), by computerized interpretation of the EMR content (a 
posteriori derivation of structured data elements from free text) or a combination of these two 
methods. The laboratory procedures, however, likely will require a priori guidelines for tissue 
handling as well as analytic protocols, and representation of the test results in a standardized 
format. Only if all data types describing patient characteristics (phenotype, genotype, and 
proteotype) are represented in a structured and standardized format, will we be able to assign 
value to the results of the new genome-based technologies, and apply these to the benefit of the 
individual patient. 
 
Disease reclassification  
 
Classification of diseases is enhanced to a molecular level by new insights in pathophysiology 
derived from functional genomics. It involves different patient characteristics like clinical 
findings and various diagnostic procedures. When classification of diseases is enhanced to a 
molecular level, knowledge from clinical research is being combined with functional 
genomics. 
 
Because of the abundance of molecular markers, it is a challenge to distinguish between 
random and clinically relevant associations. The validation of results from functional genomics 
research involves the integration of complex databases from MI concerning clinical 
information and BI with respect to the genome data. High data quality, appropriate sample 
sizes and common data models are important success factors for this validation process. 
 
Informatics for supporting rational drug design and development  
 
Post-genomic tools are already well integrated into many of the key steps of the drug 
development pipeline, including target identification and validation, lead compound finding 
and optimisation, toxicity studies, patient typing and stratification for clinical phases. The 
implementation of these new technologies is aimed at increasing efficiency, reducing time to 
market and ultimately cost.  
 
 
 
For historical pre-genomic and perhaps other pragmatic reasons the drug pipeline is geared for 
a “shot-gun” wet-lab approach to the target and lead compound discovery and development 
process. This approach fails to take full advantage of the post-genomic era. With more than 
10,000 potential targets the opportunity to dramatically transform the drug discovery process 
through a combined in silico and lead compound development pipeline has so far been 
overlooked. There exists excellent opportunity to merge fields such as BI/ cheminformatics, 
protein and DNA microarray technology with MI in preclinical and clinical toxicity, patient 
typing and stratification.  
 
b. BI IN SUPPORT OF INDIVIDUALIZED HEALTHCARE 
 
Bioinformaticians are playing a key role in the acquisition, processing and analysis of 
individual genetic information (SNPs, haplotypes). Therefore they can and should help to 
integrate genetic data obtained in functional and comparative (individual) genomics into the 
clinical information systems to aid in a true personalised healthcare. Knowledge of the 
concepts involved in acquiring, representing, analysing, and integrating such data will be 
essential in effectively applying molecular information in the diagnosis and treatment of 
complex medical disorders by the practicing clinician. 
Including genetic data into the electronic health record  
Current electronic health care records contain an increasing amount of coded, structured 
data. Although genetic data are beginning to be included in electronic health records, current 
records have not been designed to include the specific requirements of genetic data. As a result, 
the genetic data are typically recorded as "laboratory data" on the individual patient. 
Consequently, the use of the data is limited (e.g., family relationships are often recorded only 
minimally, limiting the possibilities to study relationships among the phenotypes of relatives). 
Based on the (expected) use of genetic data in health care, models need to be developed that 
will support the optimal use of the data in electronic health records. Optimal use will have to 
include the use of the data to provide decision support to the treating physician based on the 
available genetic data. 
  
Methods for personalized health care: guidelines and decision making support systems 
 
Clinical guidelines are standard means for dissemination of clinical knowledge and the support 
of physicians in the course of decision-making. Using genetic information can further improve 
decision-making quality. 
 
Clinical guidelines are text documents (in paper or electronic form) containing various sorts of 
recommendations for the diagnosis, treatment and prevention of particular diseases. The task 
for which the computerized guidelines are most commonly used is the support of the clinician 
in the course of decision-making. Due to the safety-critical character of such online 
applications, they rely on complex knowledge representation and on combination of multiple 
inference strategies. Still, interaction with the medical staff is frequently needed. An example 
of a guideline-based decision support is the Stanford-based EON system. Combining clinical 
and genetic information and using nowadays decision- support and knowledge -based system 
decision-making quality can further improve quality of care in individual. Diagnosis and 
 
 
therapy of diseases will be individualized with the support of genetic knowledge based systems 
and molecular expert systems.  
Telegenetics 
Telemedicine services are a reality nowadays, covering many scenarios (e.g. teleconsultation, 
remote monitoring, training and education, emergency, tele-surgery) and medical specialities 
(e.g. radiology, cardiology, obstetrics, pathology, psychiatry, genetics).  
In the domain of genetic medicine there are currently a significant number of services being 
delivered using telemedicine. Services in the domains of cancer genetics, clinical genetics and 
reproductive genetics can be found in the literature. In fact, many genetic centres that routinely 
utilize phone consults with physicians and phone interactions with patients to help determine 
the need for genetic services or to prepare for an appointment, are moving to Internet based 
services, and incorporating all the needed security and confidentiality requirements. For 
genetic counsellors and medical geneticists telemedicine is a powerful tool bringing together 
multiple kinds of distributed information: personal and family history, physical findings, and 
radiology and pathology results. 
Stratifying patients by their genetic profiles: molecular diagnosis, clinical trials and 
pharmacogenomics  
One of the benefits of the study of the human genome is the identification of the SNPs and 
haplotypes present in the human population. With this information at hand the stratification of 
people based on their genetic profile would allow to further the knowledge of the interactions 
between the environment and genetic traits and how they affect the development of diseases. 
Information on the different genotypes together with phenotypic and environmental 
information would allow to better design clinical trials and to ultimately optimise treatments. 
This new therapeutic approach may facilitate the merging of diagnosis and pharmacology, 
hence the possibility of personalized medicine. There will be a need for a BMI infrastructure to 
make possible the integration and posterior management of this genetic and environmental data 
into clinical trials, and the design of personalised therapeutic interventions based on the 
available information. 
 
Point-of-care data collection and access  
 
At present, genetic data are typically collected by (larger) clinical or research laboratories. New 
DNA / protein detection technologies are developing rapidly (e.g. biochips or lab-on-a-chip) 
and will not require a complete laboratory environment to perform a test. The new analytical 
devices offer the possibility of accessing patients’ e.g. genetic profiles within reasonable time 
and expenses at the point-of-care. These advances bring along a large number of challenges for 
the data processing, handling, distribution and storage.  
 
? Interoperability and connectivity of point-of-care devices, data acquisition and analysis 
systems. 
? Analytical devices as combined collectors of medical and genetic information, temporary 
repository of data, data query devices, and data entry point for MI-BI systems.   
? Patient self testing and Web based software applications in the frame of individualized 
medicine. 
 
 
? Support of individual diagnostic and therapy by genetic and proteomic data. 
 
If general practitioners are going to be able to obtain these data, they will also need to access 
other complementary data, place them in context and assure their processing under quality 
criteria. 
 
Complexity in characterising genomic and phenotypic microbial diversity related to infectious 
diseases (Microbial genomics) 
 
Microbial genomics means whole-genome sequencing coupled with BI tools to facilitate the 
assembly, gene prediction, and functional annotation. This approach has revolutionised our 
understanding of the biology of important human microbial pathogens. Comparative genome 
analysis provides insights into adaptations of microbes to their ecological niches and allows the 
detection of factors that shape host-pathogen interactions.  
There is considerable evidence that genetic polymorphisms in both the microbial pathogen and 
host can impact on microbial virulence or host immune responses to infection. The elucidation 
of microbial pathogen genomes will contribute to the characterisation of genomic and 
phenotypic microbial diversity related to infectious diseases, will allow the rapid identification 
of microbial pathogens by means of genetic markers, and will shed light on the mechanisms of 
pathogenicity and antibiotic resistance. 
 
c. BIOMEDICAL INFORMATICS IN SUPPORT OF GENOMIC MEDICINE  
A new approach to the processing of information about diseases and health, in which all levels 
of information (from the molecule to the population, going through the cell, the tissue, the 
organ, the patient and the disease itself) would be integrated. The appropriate techniques and 
methods would be applied in each case; some would come from BI and others from MI and 
even from public health and epidemiology informatics. The objective is to process, as 
efficiently as possible, all the information coming from biological, clinical and environmental 
research and to advance in the development of Molecular and Personalised Medicine.  
 
Molecular and functional imaging 
 
Molecular Imaging is broadly defined as the characterization and measurement of biological 
processes in living animals -- including humans -- at the tissue, cellular and molecular level. In 
terms of healthcare, the dream is that pre-symptomatic diagnosis and treatment will be 
possible. 
 
The challenge is to help medical doctors see a disease earlier than it is traditionally seen today, 
better diagnose, prescribe and monitor therapy. Molecular imaging will build on existing 
technologies in Positron Emission Tomography (PET), Computerized X-ray Tomography 
(CT), high-field Magnetic Resonance (MR) and MR Spectroscopy, optical imaging, and image 
analysis. Significant informatics tools are needed to support molecular imaging. There fall into 
two types:  
? MI to Understand Correlations. This includes biostatistics and machine learning to identify 
significant imaging, genomic, and clinical factors to answer, predict and prognose 
important clinical questions. 
 
 
? BI to Elucidate Molecular Disease Pathology. This includes integrated genomic and 
protein-interaction databases, pathway elucidation, analysis, modelling and simulation, and 
predication. 
 
Much molecular imaging research funding is focused on cancer, but we see opportunities in 
cardio-vascular disease as well as neurological diseases such as Alzheimer's. 
 
Modelling and simulation for an integrative approach of physiology and pathology  
The discovery and evaluation of diagnostic and therapeutic agents will be accelerated and 
made less costly through the creation and use of integrated dynamic models of processes taking 
place in cells and tissues. These in silico models will combine, unify, and reconcile genomic 
and proteomic data for understanding of complex diseases involving many molecular species 
and many cellular states. BI and MI professionals can largely contribute to it. 
 
This approach will be strongly supported by results derived from the theory of non-linear 
dynamical systems, by recent advances in the measurement of dynamic processes in individual 
living cells, and by characterization of physical properties of biological objects, from elasticity 
of DNA to mechanical properties of cells and tissues in different physio-pathological 
situations. 
 
These models can be built by combining two complementary approaches: (1) top-down, from 
clinical manifestations to inner mechanisms and (2) bottom-up, from molecules to clinical 
manifestations. Only formal models can provide a unified abstraction for dealing with the 
inherent multi-scale, complexity, non-linearity and self-organisation of living systems, 
diversity of patho-physiological processes, and design of optimal diagnosis and therapy.  
 
? Development of multi-level dynamical models that would account for spatio-temporal 
organisation and adaptations from the molecular/cellular levels to the higher processing 
levels of tissue and organ physiology. While this is a very hard field where only 
preliminary models can be developed, it is at the centre of the scientific elucidation of 
relationships between information, regulation and organisation of organisms.  
? Realistic, high resolution in silico models of the entire cell, its processes, and its 
environment. The capability of testing various hypotheses should be made available in in 
silico models that overcome the limitations of cell simulation models such as those of 
Electronic Cell (http://e-cell.org/) or Virtual cell (http:// www.nrcam.uchc.edu/ 
vcell_development/ vcell_dev.html).  
? Development of shared libraries of in silico models of molecules, interactions, pathways 
and functions.  
? Image processing and interpretation of bio, gene, protein or tissue-arrays data, in particular 
those coming from isotopic, fluorescent or ultrasound sources for understanding pathway 
mechanisms in relation to specific diseases. Molecular imaging creates new challenges and 
opportunities for combining imaging data with genomic and proteomic data, but only with 
an integrative model can this be realized. 
? In silico modelling of genetic and metabolic networks should be designed to make specific 
and testable predictions about the key steps of either genetic regulations in operons or 
metabolic regulations in enzymatic pathways or in transportation chains.  
 
 
 
Epidemiology: biobanks and populational repositories  
Human genome epidemiology or genetic epidemiology is the new discipline that deals with 
collections of information on large number of tissues and samples stored in biobanks and 
populational repositories. Informatics, in this discipline, is applied to manage and analyse 
relevant data on gene-environment interactions that contribute to diseases of public health 
importance. Large amounts of molecular epidemiological data of different populations (both of 
patient and control individuals) are needed for this.  
 
The development of new genetic information technologies will make possible to perform cost-
effective screening (genetic tests) at the population level. The intersection of these genetic data 
with clinical data, electronic health records, environmental and lifestyle data will make 
possible, among other things, the unravelling of polygenetic disease causality, as well as the 
complex interactions existent in disease pathogenesis and causation. All these data obtained 
will be included in populational repositories or biobanks and this knowledge will be applied in 
public health, for instance disease prevention programs based on genetic data. Assessment of 
the cost-efficacy of pharmacogenetics approaches in health systems will also be possible.  
 
Several initiatives in the US and in Europe have already started. Some examples are the CDC 
with the HuGENet (Human Genome Epidemiology Network) and the National Cancer Institute 
in the USA and in Europe there is an ongoing project in Iceland that will link health records 
with genealogical information and information about the genotype. Other on-going projects are 
also carried out in UK and Estonia. 
 
 
New methods for e-learning in genomic-based medicine  
 
Due to the increasing amount of medical knowledge in genomic-based medicine, physicians 
will have to update their knowledge on genetics and genomics. It seems unreasonable to think 
that this will change easily and rapidly. Research demonstrates that learning is enhanced when 
learners identify their own needs, select their own strategies and evaluate their own learning 
outcomes. Internet based informatics tools will be decisive to introduce these possible changes 
in molecular medicine in a soft manner, avoiding physicians’ rejection. The introduction of 
new learning technologies, providing open and flexible learning programmes, will be crucial 
for the improvement of doctor’s skills and knowledge.  
 
d. ENABLING TECHNOLOGIES  
 
Security 
 
Regarding bio-medical information sciences, the next few decades look very promising and as 
always, with the promise of benefits also come the danger of abuse. Genomic medicine and the 
associated interplay between aggregated data and individual data have e.g. given rise to 
concerns about the proper collection, storage and processing of individually identifiable 
sensitive information. A focus is needed on privacy enhancing and protecting measures. 
Besides the more traditional security issues dealing with e.g. confidentiality, integrity, 
availability, accountability more advanced Privacy Enhancing Techniques (PETs) need to be 
 
 
addressed. These techniques are of even more importance when storing, exchanging and 
processing not only medical but also genetic data. 
 
With respect to threats against privacy, there are striking risk differences between genetic and 
medical data: genetic data concern not only individuals, but also their relatives, i.e. people who 
have not been tested directly; personal genetic profiles can be directly derived from tissue 
samples; medical data deal with the past or current health status of persons, whereas genetic 
tests also furnish indications about future health or disease conditions; an individual genotype 
is almost unique and stable. 
 
Examples of privacy related issues and techniques are: anonymisation, pseudonymisation, data 
linkage, gauging for direct and indirect re-identification risks in databases and GRID 
environments, systems for controlled database dilution, privacy enhancing intelligent agents. 
 
Communication standards – Interoperability among clinical and genetic information systems  
 
Communication between all levels is necessary and has to be provided in a trustworthy way. 
This means services have to be developed, implemented and maintained for communication 
security and application security for heterogeneous distributed networks. 
 
Interoperability is the prerequisite for communication and must be addressed in following 
areas: 
? Data and knowledge (structure, representation, terminology,..) 
? Technique (architecture, hardware, topology) 
? Presentation of data and knowledge, 
? Security for systems, health care professionals and patients 
 
Standards used today include electronic health records (EHRs, CEN ENV13606), HL7, 
knowledge representation in GLIF (Guideline interchange format) and Arden syntax, health 
professional and patient cards, IP and other protocols. XML and XSL present the bigger 
potential to become the standard language for BMI. An integrated approach using a component 
based architecture will be an effective basis for further development in this new discipline. 
 
Knowledge representation to facilitate the virtual integration of heterogeneous clinical and 
genetic databases. 
 
Given the increasing availability of biomedical information located at different sites and 
accessible over Internet, researchers need new methods to integrate such information. 
Researchers also need novel methods to search, access, and retrieve this information, which 
must be gathered, classified and interpreted. To integrate distributed and heterogeneous 
databases two levels of heterogeneity must be considered: i) databases may be located at 
various platforms, spread over Internet, with different architectures, operating systems and 
database management systems, and ii) databases can present different conceptual data models 
and different underlying database schemas. Solutions for these problems include, for instance, 
standards such as XML, for exchanging information, or HL7, for connecting biomedical 
devices. Regarding the integration of databases, various approaches can be considered, such as 
the concept of data warehouses, federated databases or virtual repositories. 
 
 
 
To this date, there is no integrated system of knowledge representation and management that 
can give answers to the new challenges that the new genomic medicine will bring about. 
Clinicians have their own systems (ULMS, SNOMED, MeSH, ICD…), in which the coverage 
of genetic terms (mutation, gene expression) is clearly insufficient. Bioinformaticians are 
developing several ontologies (MGED, GO, HUGO) but the clinical annotation of their 
samples (organ, pathology) is still a pending subject. Rather than focusing on the unlikely 
possibility of a single terminology to cover all domains, the emphasis should be on semantic 
mapping between terminologies (including clinical and “non-clinical”.) 
 
For useful biomedical development, multiple terminologies are required. Not only are multiple 
terminologies required to cover the words used to describe the clinical state (phenotype), but 
also additional terminologies are required to leverage genomic/post genomic information for 
many other uses.   
 
Data and text–based knowledge discovery 
Data mining is a step in the process of knowledge discovery in databases. It includes 
techniques for query databases, on-line analytical processing and machine learning algorithms, 
among others. 
In the fields of medicine and biology, the enormous growth of information and databases, 
which are openly available for research, has led developers to focus on extracting knowledge 
from raw data. In the medical area, many applications have been created for decision support, 
in issues such as image and signal analysis or in clinical prognosis of patient conditions. In 
biology, efforts have been centred on research issues such as the prediction of protein 
structures and drug studies. Both offer considerable issues and challenges for future research. 
 
Text mining is a discipline consisting of several methods oriented towards extraction of data, 
information or knowledge from texts. It is strongly emerging for two reasons: first, the 
multilingual natural language processing (NLP) tools have been improved and the computing 
power of any modern desktop computer make such an approach available to any end-user; 
second -especially with the development of the web and digital libraries - the increasing 
quantity of data available in electronic format challenges the human ability to handle the 
amount of knowledge. 
 
Data and text mining are somewhat dependent on the natural language in use. When screening 
the scientific literature, the English language and the associated tools are adequate. This is 
basically the situation for BI. However, when screening patient medical records, all European 
languages are candidate and the necessary multilingual NLP tools are possibly not available. 
This is partly the situation of MI. In the future, the need to prepare and make available 
multilingual tools is recognized. To cope with structured as well as free-text repositories, 
bridges have to be built between national languages and the standardized vocabularies (like 
MeSH or SNOMED) or coding systems (HL7, TEI), in order to dispose for research purposes 
of a European corpus of EHR, for the benefit and crossfertilisation between BI and MI. 
 
 
 
 
 
 
 
Health Grid, an infrastructure on which to build the synergy between BI and MI  
 
The interconnection of computers using the Grid middleware enables the user to use computing 
power and retrieve information from heterogeneous and distributed sources without having to 
choose which machine he wants to connect to. Grids should be deployed to address the needs 
of the biomedical community using the state of the art of the middleware technology. Today, 
Grid technology is still under development and standards are just emerging. Based on the Grid 
technologies, the vision is to create an environment where information at the 5 levels 
(molecule, cell, tissue, individual, population) can be associated to provide individualised 
healthcare 
 
In the last years, the term Grid evolved towards a concept of ubiquitous and transparent 
computing and encompassed the vision of intensive computing as well as of knowledge Grid, a 
sort of all-knowing magic mirror. The key question Grid might be able to answer is: How to 
make information on all levels from molecular to population accessible and understandable to 
the large variety of people, which could benefit from such knowledge. 
 
Therefore, it is necessary that a pioneering work be done in the field of bio-informatics and MI 
on a Grid. The creation of a HealthGRID community and first collaboration through providing 
basic common services (web portals, computing resources) could be a first step in this 
direction. 
 
A further step would be the development of generic grid metadata management tools, the 
services would be extended for instance to replication, mirroring and release management of 
biological data bases and remote medical data acquisition and storage. The design of specific 
data management and data analysis tools for biological and medical imaging data would open 
the door to data mining, distributed data management, modelling and processing of 3D and 
dynamic 3D structures, among others. 
 
Conclusion 
 
The research agenda proposed would allow to increase the knowledge and advance in the 
research of both functional genomics and genomic-based medicine through the development 
and implementation of the enabling technologies and of the other research lines described. We 
believe that this would be facilitated and best achieved by the synergy of Bioinformatics and 
Medical Informatics. 
 
 
Priorities in R&D   
 
Barriers Proposed solution Priority* Risk* 
ENABLING TECHNOLOGIES 
High computational and data management 
requirements Grid             High Low 
Strong privacy issues associated to the nature of 
genetic data Security       High High 
Need to expand current interoperability standards for 
new genetic data infrastructure Data communication standards
High Medium 
Heterogeneity of current clinical and genetic sources 
and databases. Different representation systems (i.e. 
ontologies) in medicine and biology.  
Knowledge representation to 
facilitate the virtual integration 
of heterogeneous clinical and 
genetic databases 
High Low 
 
Data and text growing exponentially lacking tools to 
analyse them Data and text mining 
High Low 
MI IN SUPPORT OF FUNCTIONAL GENOMICS 
Patient care data are not been used systematically in 
genomic research.  
Phenotype databases suitable 
for genomic research 
High Low 
Lack of accepted standards for clinical validation of 
results obtained from functional genomics research Disease reclassification  
High High 
Lack of adequate matching between biomedical data 
and pharmaceutical targets Pharmacogenomics 
High Medium 
BI IN SUPPORT OF INDIVIDUALIZED HEALTHCARE 
Unavailability of models for including genetic data 
into Electronic Health Records 
Genetics data model for the 
EHR 
Medium Medium 
Increased complexity in medical decision making due 
to new genetic knowledge  
Clinical guidelines and 
decision making using genetic 
information 
Medium Medium 
Scarce and non-uniform geographic distribution of 
clinical genetics specialists and resources Telegenetics 
High Low 
Methods needed for stratifying patients by genetic 
profiles in the context of clinical research  
New methods and information 
platforms to manage genetic 
data in clin. research 
High Medium 
Lack of interoperable devices to collect genetic data 
and include them in clinical information systems 
Point-of care data acquisition 
systems  Medium Medium 
Complexity in characterising genomic and phenotypic 
microbial diversity related to infectious diseases Microbial genomics 
Medium Low 
BMI IN SUPPORT OF GENOMIC MEDICINE 
Lack of high resolution systems to correlate anatomical 
structures to physiological and genetic mechanisms 
Molecular and  
functional imaging 
Medium Low 
Lack of unified approaches to understanding and 
modelling the human body and human diseases. Modelling and simulation 
Medium Medium 
Linking environmental and lifestyle information to 
genetic and clinical data  Populational repositories 
High Low 
Narrow view of genetics and genomics in health 
professionals and patients e-Learning High High 
 
* The priorities and risks arise from the debates and discussions in the meetings of the project, the results of the 
questionnaires sent to the experts and from the opinion of the experts developing each of the lines. 
 * Risk refers to the risk of failure to deliver results. 
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